Grade 3 Hepatotoxicity following Fulvestrant, Palbociclib, and Erdafitinib Therapy in a Patient with ER-Positive/PR-Negative/HER2-Negative Metastatic Breast Cancer: A Case Report

A 49-year-old woman with ER-positive/PR-negative/HER2-negative metastatic breast cancer experienced Grade 3 hepatotoxicity following initiation of a clinical trial of fulvestrant, palbociclib, and erdafitinib. Fulvestrant was determined to be the drug most likely responsible for this hepatotoxic eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Schlotman, Alyssa, Stater, Adam, Schuler, Kyle, Heideman, Judd, Abramson, Vandana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154258/
https://www.ncbi.nlm.nih.gov/pubmed/32308596
http://dx.doi.org/10.1159/000506442

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154258/
https://www.ncbi.nlm.nih.gov/pubmed/32308596
http://dx.doi.org/10.1159/000506442

Ejemplares similares